178 related articles for article (PubMed ID: 25996952)
21. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells.
Li X; Xu YB; Wang Q; Lu Y; Zheng Y; Wang YC; Lübbert M; Zhao KW; Chen GQ
J Cell Physiol; 2006 Sep; 208(3):594-601. PubMed ID: 16741927
[TBL] [Abstract][Full Text] [Related]
22. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein.
Zhen T; Wu CF; Liu P; Wu HY; Zhou GB; Lu Y; Liu JX; Liang Y; Li KK; Wang YY; Xie YY; He MM; Cao HM; Zhang WN; Chen LM; Petrie K; Chen SJ; Chen Z
Sci Transl Med; 2012 Mar; 4(127):127ra38. PubMed ID: 22461642
[TBL] [Abstract][Full Text] [Related]
23. Transcription of the AML1/ETO chimera is guided by the P2 promoter of the AML1 gene in the Kasumi-1 cell line.
Markova EN; Kantidze OL; Razin SV
Gene; 2012 Dec; 510(2):142-6. PubMed ID: 22995345
[TBL] [Abstract][Full Text] [Related]
24. Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis.
Lu Y; Xu YB; Yuan TT; Song MG; Lübbert M; Fliegauf M; Chen GQ
Leukemia; 2006 Jun; 20(6):987-93. PubMed ID: 16598301
[TBL] [Abstract][Full Text] [Related]
25. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
26. AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis.
Singh AA; Mandoli A; Prange KH; Laakso M; Martens JH
Oncotarget; 2017 Feb; 8(8):12855-12865. PubMed ID: 28030795
[TBL] [Abstract][Full Text] [Related]
27. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
Matsuno N; Osato M; Yamashita N; Yanagida M; Nanri T; Fukushima T; Motoji T; Kusumoto S; Towatari M; Suzuki R; Naoe T; Nishii K; Shigesada K; Ohno R; Mitsuya H; Ito Y; Asou N
Leukemia; 2003 Dec; 17(12):2492-9. PubMed ID: 14562119
[TBL] [Abstract][Full Text] [Related]
28. Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia.
Niu J; Li H; Zhang Y; Li J; Xie M; Li L; Qin X; Qin Y; Guo X; Jiang Q; Liu Y; Chen S; Huang X; Han W; Ruan G
Leuk Res; 2011 Jun; 35(6):771-6. PubMed ID: 21168207
[TBL] [Abstract][Full Text] [Related]
29. Correlation between FLT3-ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias.
Souza Melo CP; Campos CB; Dutra ÁP; Neto JC; Fenelon AJ; Neto AH; Carbone EK; Pianovski MA; Ferreira AC; Assumpcão JG
Leuk Res; 2015 Feb; 39(2):131-7. PubMed ID: 25530565
[TBL] [Abstract][Full Text] [Related]
30. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
33. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
Reikvam H; Hatfield KJ; Ersvaer E; Hovland R; Skavland J; Gjertsen BT; Petersen K; Bruserud O
Br J Haematol; 2012 Feb; 156(4):468-80. PubMed ID: 22150087
[TBL] [Abstract][Full Text] [Related]
34. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
35. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
[TBL] [Abstract][Full Text] [Related]
36. Reduced Expression of Metastasis Suppressor-1 (MTSS1) Accelerates Progression of Human Bladder Uroepithelium Cell Carcinoma.
Du P; Wang S; Tang X; An C; Yang Y; Jiang WG
Anticancer Res; 2017 Aug; 37(8):4499-4505. PubMed ID: 28739745
[TBL] [Abstract][Full Text] [Related]
37. FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1.
Kim M; Kim J; Kim JR; Han E; Park J; Lim J; Kim Y; Han K; Kim HJ; Min WS; Cho B
Mol Biol Rep; 2015 Feb; 42(2):451-6. PubMed ID: 25287662
[TBL] [Abstract][Full Text] [Related]
38. miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1.
Xu L; Zhong J; Guo B; Zhu Q; Liang H; Wen N; Yun W; Zhang L
Tumour Biol; 2016 Sep; 37(9):12023-12032. PubMed ID: 27164937
[TBL] [Abstract][Full Text] [Related]
39. [Expression of survivin in patients with acute myeloid leukemia].
Sun WX; Zhang PH; Fang LH; Tian Z; Tang KJ; Rao Q; Wang M; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1099-104. PubMed ID: 24156414
[TBL] [Abstract][Full Text] [Related]
40. RUNX1/ETO regulates reactive oxygen species (ROS) levels in t(8,21) acute myeloid leukaemia via FLT3 and RAC1.
Azlan A; Khor KZ; Rajasegaran Y; Rosli AA; Said MSM; Yusoff NM; Moses EJ
Med Oncol; 2023 Jun; 40(7):208. PubMed ID: 37341821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
